Back

Role of serum biomarkers for monitoring disease progression in the cardio-specific alpha-galactosidase A genotype N215S

27 August 2017 (10:05 - 10:55)
Organised by:
Congress Presentation Part of: Cardiomyopathy in Fabry disease Cardiomyopathies ESC Premium Access ESC Congress 2017

About the speaker

Photo
Doctor Daniel Oder

Wuerzburg (Germany)

6 More presentations in this session

Presentation thumbnail
Comprehensive cardiovascular magnetic resonance assessment of anderson-fabry cardiomyopathy- natural history and assessment of treatment effect
Doctor A. Reid (Manchester, GB)
Abstract Slides
Presentation thumbnail
Treatment of Fabry disease with a new oral drug: Initial real-world single-center experience
Mr J. Muentze (Wuerzburg, DE)
Abstract
Presentation thumbnail
Prompt initiation of agalsidase alfa therapy is associated with improved cardiovascular outcomes in the Fabry Outcome Survey
Professor A. Linhart (Prague, CZ)
Abstract Slides
Presentation thumbnail
Efficacy of enzyme replacement therapy in Fabry disease with advanced organ involvement
Doctor P. Nordbeck (Wuerzburg, DE)
Abstract
Presentation thumbnail
Long-term benefit of enzyme replacement therapy on cardiac manifestation in Japanese Fabry disease
Doctor I. Anan (Tokyo, JP)
Abstract Slides

Access the full session

Session thumbnail
Cardiomyopathy in Fabry disease

The Event

Event poster

ESC Congress 2017

27 August 2017 10:05 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources